<DOC>
	<DOCNO>NCT02279641</DOCNO>
	<brief_summary>This Phase 1b , randomize , open-label , drug-drug interaction study adult male subject gout . It design assess pharmacokinetics ( PK ) pharmacodynamics ( PD ) RDEA3170 allopurinol alone combination feed state .</brief_summary>
	<brief_title>RDEA3170 Allopurinol Combination Study Gout Subjects</brief_title>
	<detailed_description />
	<mesh_term>Gout</mesh_term>
	<mesh_term>Allopurinol</mesh_term>
	<criteria>Subject meet one criterion diagnosis gout per American Rheumatism Association Criteria Classification Acute Arthritis Primary Gout . Subject body weight ≥ 50 kg ( 110 lb . ) body mass index ≥ 18 ≤ 45 kg/m2 . Subject Screening serum urate level ≥ 8 mg/dL ≤ 10 mg/dL Subject free clinically significant disease medical condition , per Investigator 's judgment . Subject unable take colchicine gout flare prophylaxis . Subject history suspicion kidney stone . Subject estimate creatinine clearance &lt; 60 mL/min calculate CockcroftGault formula use ideal body weight Screening prior Day 2 . Subject unstable dos chronic medication . Subjects take medication chronic medical condition must stable dos course study , include Screening period . Dose adjustment allow deem medically necessary investigator follow discussion medical monitor Chronic stable dos losartan , fenofibrate , guaifenesin , sodiumglucose link transporter2 inhibitor permit dose stable least 14 day prior study medication dosing . Subject unable unwilling comply study requirement situation condition , opinion Investigator , may interfere participation study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>